These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12712417)

  • 21. Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler®.
    Hoe S; Young PM; Traini D
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1365-75. PubMed ID: 21554161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations.
    El-Sabawi D; Price R; Edge S; Young PM
    Drug Dev Ind Pharm; 2006 Feb; 32(2):243-51. PubMed ID: 16537205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Leuenberger H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1326-30. PubMed ID: 11605663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers.
    Larhrib H; Martin GP; Prime D; Marriott C
    Eur J Pharm Sci; 2003 Jul; 19(4):211-21. PubMed ID: 12885385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose.
    Pinto JT; Zellnitz S; Guidi T; Roblegg E; Paudel A
    Mol Pharm; 2018 Jul; 15(7):2827-2839. PubMed ID: 29856921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations.
    Molina C; Kaialy W; Chen Q; Commandeur D; Nokhodchi A
    Drug Deliv Transl Res; 2018 Dec; 8(6):1769-1780. PubMed ID: 29260462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach.
    Hooton JC; Jones MD; Price R
    J Pharm Sci; 2006 Jun; 95(6):1288-97. PubMed ID: 16637052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spray dried mannitol carrier particles with tailored surface properties--the influence of carrier surface roughness and shape.
    Littringer EM; Mescher A; Schroettner H; Achelis L; Walzel P; Urbanetz NA
    Eur J Pharm Biopharm; 2012 Sep; 82(1):194-204. PubMed ID: 22595133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles.
    Tan BM; Chan LW; Heng PW
    Pharm Res; 2016 Aug; 33(8):1923-35. PubMed ID: 27091033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
    Flament MP; Leterme P; Gayot A
    Int J Pharm; 2004 May; 275(1-2):201-9. PubMed ID: 15081150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lactose composite carriers for respiratory delivery.
    Young PM; Kwok P; Adi H; Chan HK; Traini D
    Pharm Res; 2009 Apr; 26(4):802-10. PubMed ID: 19015956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems.
    Ooi J; Traini D; Hoe S; Wong W; Young PM
    Int J Pharm; 2011 Jul; 413(1-2):1-9. PubMed ID: 21501674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.